Indian Health Ministry seeking compulsory license for B-MS' Sprycel
Anti leukemia drug dasatinib, made by US pharma major Bristol-Myers Squibb (NYSE: BMY) and sold in India under the brand name Sprycel, could be in the dock once again, with the Health Ministry requesting anew the grant of a compulsory license for the cancer drug, reports The Pharma Letter's India correspondent.
Earlier, a Health Ministry proposal to consider a government initiated compulsory licence for dasatinib was shot down by the Department of Industrial Policy and Promotion (DIPP), the nodal department of the government of India handling intellectual property matters, on the ground that it is unaffordable. The Health Ministry has held that the high priced, patent protected anti cancer drug is out of reach of several patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze